Gridsum News October 9th | Innocare (688428.SH) announced recently that its innovative drug ICP-488 has achieved positive clinical trial results in a phase II randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis. ICP-488 is a potent and highly selective oral TYK2 (tyrosine kinase 2) inhibitor that binds to the TYK2-JH2 domain, blocking the signaling of inflammatory cytokines such as IL-23, IL-12, and type I interferons, thereby inhibiting the pathological processes of autoimmune and inflammatory diseases.
This phase II clinical trial is a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ICP-488 in treating moderate to severe plaque psoriasis. The primary endpoint of the study was a reduction of at least 75% in the Psoriasis Area and Severity Index (PASI) score at week 12. The study results showed that patients treated with 6mg and 9mg (once daily) of ICP-488 had significant improvements in PASI75 at week 12 compared to patients receiving placebo. Furthermore, the proportion of patients achieving PASI90, PASI100, and static Physician's Global Assessment (sPGA) 0/1 (complete or almost complete clearance of lesions) in the group receiving ICP-488 treatment was significantly higher than in the placebo group.
